Grounded in science, we explore and validate novel targets with rigor and resolve, paving the way toward breakthrough therapies for immunological diseases and cancer.
We are taking a novel approach to targeting SIRP
Our portfolio of Signal Regulatory Proteins (SIRP)-directed antibodies work via a unique mechanism of action and have the potential to address the underlying pathology across a broad range of diseases.
We are committed to tackling therapeutic challenges in areas with critical unmet needs and empowering patients with breakthrough treatments.
